CSL Behring Supports Rare Disease Day 2026 with Special Initiatives CSL Behring participates as a diamond sponsor for Rare Disease Day 2026, promoting awareness through a special radio program.

CSL Behring Supports Rare Disease Day 2026 with Special Initiatives #Japan #Rare_Disease_Day #CSL_Behring #Minato,_Tokyo #RARE_LiNK_PROJECT

CSL Behring Joins Santa Parade 2025 to Support Children Battling Illness CSL Behring participates in the Santa Parade 2025 to support children fighting illnesses and forge community connections. Join us in this noble cause!

CSL Behring Joins Santa Parade 2025 to Support Children Battling Illness #Japan #Tokyo #community_support #CSL_Behring #Santa_Parade

CSL Behring Wins Prestigious 2025 ISPE Facility of the Year Award for Innovative Project Aurora CSL Behring celebrates winning the 2025 ISPE Facility of the Year Award for its groundbreaking Project Aurora, showcasing innovation in pharmaceutical manufacturing.

CSL Behring Wins Prestigious 2025 ISPE Facility of the Year Award for Innovative Project Aurora #United_States #Charlotte #CSL_Behring #Project_Aurora #ISPE_FOYA

CSL Behring Publishes Archive of HAE Online Public Lecture on Patient Challenges CSL Behring has released an archive of an online public lecture on hereditary angioedema, focusing on patient experiences and challenges. This initiative aims to improve quality of life for HAE patients.

CSL Behring Publishes Archive of HAE Online Public Lecture on Patient Challenges #Japan #Tokyo #HAE #CSL_Behring #Hereditary_Angioedema

CSL Reports Strong FY2025 Financial Results with Strategic Transformations Ahead CSL reports a notable increase in net profit for FY2025, driving strategic initiatives to enhance growth. Key plans include a proposed demerger and operational efficiencies.

CSL Reports Strong FY2025 Financial Results with Strategic Transformations Ahead #Australia #Melbourne #CSL_Behring #CSL_Limited #CSL_Seqirus

CSL Behring Initiates RARE LiNK PROJECT to Support Rare Disease Patients CSL Behring launches the RARE LiNK PROJECT, a new initiative to connect and support individuals facing rare diseases, fostering community engagement.

CSL Behring Initiates RARE LiNK PROJECT to Support Rare Disease Patients #Japan #Tokyo #Rare_Diseases #CSL_Behring #RARE_LiNK

CSL Behring Launches New Gene Therapy Information Site for Patients and Families CSL Behring has launched the 'Gene Therapy Portal' to provide essential information on gene therapy for patients and families, promoting better understanding.

CSL Behring Launches New Gene Therapy Information Site for Patients and Families #Japan #Tokyo #gene_therapy #CSL_Behring #Patient_Education

CSL Behring's ANDEMBRY® Receives Approval for HAE Treatment in Japan CSL Behring announces the approval of ANDEMBRY®, a novel treatment for hereditary angioedema, marking a significant advancement in patient care.

CSL Behring's ANDEMBRY® Receives Approval for HAE Treatment in Japan #Japan #Tokyo #HAE #CSL_Behring #ANDEMBRY

European Commission Grants Approval for CSL's ANDEMBRY® as a New Treatment for Hereditary Angioedema CSL's ANDEMBRY® is now approved by the European Commission as the first monthly treatment for hereditary angioedema, providing hope for patients.

European Commission Grants Approval for CSL's ANDEMBRY® as a New Treatment for Hereditary Angioedema #Germany #Garadacimab #Marburg #CSL_Behring #ANDEMBRY

HEMGENIX® Delivers Sustained Efficacy and Safety for Hemophilia B Therapy Even After Four Years The four-year data reveals HEMGENIX®'s efficacy and safety, showing 94% of hemophilia B patients are free from continuous prophylaxis.

HEMGENIX® Delivers Sustained Efficacy and Safety for Hemophilia B Therapy Even After Four Years #United_States #King_of_Prussia #HEMGENIX #Hemophilia_B #CSL_Behring